An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate

Angew Chem Int Ed Engl. 2021 Dec 6;60(50):26403-26408. doi: 10.1002/anie.202113562. Epub 2021 Nov 5.

Abstract

Glatiramer acetate (GA) is a random polypeptide drug used to treat multiple sclerosis (MS), a chronic autoimmune disease. With the aim of identifying a precisely defined alternative to GA, we synthesized a library of peptide dendrimers with an amino acid composition similar to GA. We then challenged the dendrimers to trigger the release of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) from human monocytes, which is one of the effects of GA on immune cells. Several of the largest dendrimers tested were as active as GA. Detailed profiling of the best hit showed that this dendrimer induces the differentiation of monocytes towards an M2 (anti-inflammatory) state as GA does, however with a distinct immune marker profile. Our peptide dendrimer might serve as starting point to develop a well-defined immunomodulatory analog of GA.

Keywords: Glatiramer Acetate; dendrimers; immunomodulation; multiple sclerosis; peptides.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation / drug effects
  • Dendrimers / chemical synthesis
  • Dendrimers / chemistry
  • Dendrimers / pharmacology*
  • Glatiramer Acetate / chemistry
  • Glatiramer Acetate / pharmacology*
  • Humans
  • Immunosuppressive Agents / chemical synthesis
  • Immunosuppressive Agents / chemistry
  • Immunosuppressive Agents / pharmacology*
  • Monocytes / drug effects*
  • Peptides / chemical synthesis
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Receptors, Interleukin-1 / antagonists & inhibitors*

Substances

  • Dendrimers
  • Immunosuppressive Agents
  • Peptides
  • Receptors, Interleukin-1
  • Glatiramer Acetate